Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, ...
The Pearsanta’s MET diagnostic test uses a blood-based biomarker for detecting mitochondrial DNA for diagnosing endometriosis ...
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its majority-owned subsidiary, Pearsanta, ...
Under the Agreement, Evofem and Pearsanta will collaboratively develop a comprehensive go-to-market strategy and MET commercial plan ahead of the planned U.S. launch in mid-2025. To date ...
In tandem with this financing arrangement, Aditxt has also invested in Evofem Biosciences (OTC:EVFM), Inc., purchasing 260 shares of Series F-1 Convertible Preferred Stock for $260,000. This ...
In tandem with this financing arrangement, Aditxt has also invested in Evofem Biosciences (OTC:EVFM), Inc., purchasing 260 shares of Series F-1 Convertible Preferred Stock for $260,000.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is ...
Aditxt (NASDAQ: ADTX) , an innovation platform dedicated to accelerating promising health innovations, has reported that its Acquisition target, Evofem Biosciences (OTCQB: EVFM) , a women's health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback